Intellia Therapeutics, Inc.

NTLA

$32.34

+115.5% (1 year change)

Avg closing price

Price range

Market Cap

$1.91 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

Revenue

-

Total revenue in the last quarter.

Net Income

$-32.4 Million

Net income is all revenues minus all expenses including taxes and interest in the last quarter.

Earnings per Share

$-2.28

Earnings per share is the amount of net income that is attributed to each single share outstanding.

Dividends per Share

-

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Price-Earnings Ratio

-14.16x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

EBIT

$-33 Million

Earnings before interest expenses and taxes in the last quarter.

Employees

270

The number of full time employees.

Revenue & Earnings

Balance Sheet

Intellia Therapeutics, Inc.

Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

News

Intellia Therapeutics Factors Likely to Have Influenced Earnings Results Stock market Insights & financial analysis

Intellia Therapeutics Factors Likely to Have Influenced Earnings Results Stock market Insights & financial analysis

Intellia Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…

Stock Market Daily Stock Market Daily, 26 days ago
Intellia Therapeutics (NASDAQ:NTLA) Shares Gap Down to $24.81

Intellia Therapeutics (NASDAQ:NTLA) Shares Gap Down to $24.81

Intellia Therapeutics Inc (NASDAQ:NTLA)’s stock price gapped down before the market opened on Friday . The stock had previously closed at $24.81, but opened at $22.50. Intellia Therapeutics shares ...

Daily Political Daily Political, about 1 month ago
Navidea Biopharmaceuticals (NYSE:NAVB) and Intellia Therapeutics (NYSE:NTLA) Head-To-Head Contrast

Navidea Biopharmaceuticals (NYSE:NAVB) and Intellia Therapeutics (NYSE:NTLA) Head-To-Head Contrast

Navidea Biopharmaceuticals (NYSE:NAVB) and Intellia Therapeutics (NASDAQ:NTLA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on t...

 Dakota Financial News Dakota Financial News, about 1 month ago